Guizhou Yibai Pharmaceutical Co Ltd

SHG:600594 China Drug Manufacturers - Specialty & Generic
Market Cap
$507.28 Million
CN¥3.72 Billion CNY
Market Cap Rank
#11561 Global
#2646 in China
Share Price
CN¥4.70
Change (1 day)
-2.08%
52-Week Range
CN¥3.17 - CN¥4.80
All Time High
CN¥19.64
Categories
Companies in China Drug Manufacturers - Specialty & Generic
About

Guizhou Yibai Pharmaceutical Co., Ltd. researches, develops, produces, and sells pharmaceutical products in China. It offers products in the form of capsules, tablets, granules, syrups, small-volume injections, freeze-dried powder injections, lyophilized powder injections, pills, and oral solutions in the areas of tumor system, cerebrovascular, respiratory system, rheumatic bone, digestive system… Read more

Guizhou Yibai Pharmaceutical Co Ltd (600594) - Net Assets

Latest net assets as of September 2025: CN¥2.52 Billion CNY

Based on the latest financial reports, Guizhou Yibai Pharmaceutical Co Ltd (600594) has net assets worth CN¥2.52 Billion CNY as of September 2025.

Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥3.84 Billion) and total liabilities (CN¥1.32 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.

Key Net Assets Metrics

Metric Value
Current Net Assets CN¥2.52 Billion
% of Total Assets 65.54%
Annual Growth Rate 16.19%
5-Year Change -24.75%
10-Year Change -26.59%
Growth Volatility 41.3

Guizhou Yibai Pharmaceutical Co Ltd - Net Assets Trend (2001–2024)

This chart illustrates how Guizhou Yibai Pharmaceutical Co Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.

Annual Net Assets for Guizhou Yibai Pharmaceutical Co Ltd (2001–2024)

The table below shows the annual net assets of Guizhou Yibai Pharmaceutical Co Ltd from 2001 to 2024.

Year Net Assets Change
2024-12-31 CN¥2.61 Billion -13.66%
2023-12-31 CN¥3.02 Billion -5.38%
2022-12-31 CN¥3.19 Billion -10.46%
2021-12-31 CN¥3.56 Billion +2.87%
2020-12-31 CN¥3.46 Billion -6.98%
2019-12-31 CN¥3.72 Billion -4.80%
2018-12-31 CN¥3.91 Billion -15.75%
2017-12-31 CN¥4.64 Billion +10.70%
2016-12-31 CN¥4.19 Billion +18.10%
2015-12-31 CN¥3.55 Billion +3.67%
2014-12-31 CN¥3.42 Billion +77.20%
2013-12-31 CN¥1.93 Billion +25.03%
2012-12-31 CN¥1.55 Billion +35.79%
2011-12-31 CN¥1.14 Billion +29.92%
2010-12-31 CN¥876.05 Million +23.22%
2009-12-31 CN¥710.95 Million +18.86%
2008-12-31 CN¥598.16 Million +12.85%
2007-12-31 CN¥530.04 Million +24.51%
2006-12-31 CN¥425.69 Million -22.23%
2005-12-31 CN¥547.39 Million +8.03%
2004-12-31 CN¥506.70 Million +181.16%
2003-12-31 CN¥180.22 Million +40.57%
2002-12-31 CN¥128.20 Million +55.15%
2001-12-31 CN¥82.63 Million --

Equity Component Analysis

This analysis shows how different components contribute to Guizhou Yibai Pharmaceutical Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • Retained earnings have grown by 2389.0% over the analyzed period, indicating profitable operations and earnings retention.

Current Equity Component Breakdown (December 2024)

Component Amount Percentage
Retained Earnings CN¥753.98 Million 30.28%
Common Stock CN¥791.93 Million 31.81%
Other Comprehensive Income CN¥315.02 Million 12.65%
Other Components CN¥628.83 Million 25.26%
Total Equity CN¥2.49 Billion 100.00%

Guizhou Yibai Pharmaceutical Co Ltd Competitors by Market Cap

The table below lists competitors of Guizhou Yibai Pharmaceutical Co Ltd ranked by their market capitalization.

Company Market Cap
Svolder AB (publ)
ST:SVOL-B
 		$373.20 Million
Karooooo Ltd
NASDAQ:KARO
 		$373.23 Million
YLZ Information Tech Co
SHE:300096
 		$373.30 Million
Kura Sushi USA Inc
NASDAQ:KRUS
 		$373.31 Million
Integral Diagnostics Limited
PINK:ITGDF
 		$372.93 Million
TOTAL ENERGY SERVS INC.
F:5O7
 		$372.90 Million
Wenfeng Great World Chain Development Corp
SHG:601010
 		$372.84 Million
Bridge Investment Group Holdings Inc
NYSE:BRDG
 		$372.55 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Guizhou Yibai Pharmaceutical Co Ltd's equity between the two most recent reporting periods.

Equity Growth Insights

  • From 2023 to 2024, total equity changed from 2,884,444,484 to 2,489,758,456, a change of -394,686,028 (-13.7%).
  • Net loss of 317,215,358 reduced equity.
  • Dividend payments of 86,874,598 reduced retained earnings.
  • Share repurchases of 25,004,481 reduced equity.
  • Other comprehensive income increased equity by 315,015,845.
  • Other factors decreased equity by 280,607,436.

Equity Change Factors (2023 to 2024)

Factor Impact Contribution
Net Income CN¥-317.22 Million -12.74%
Dividends Paid CN¥86.87 Million -3.49%
Share Repurchases CN¥25.00 Million -1.0%
Other Comprehensive Income CN¥315.02 Million +12.65%
Other Changes CN¥-280.61 Million -11.27%
Total Change CN¥- -13.68%

Book Value vs Market Value Analysis

This analysis compares Guizhou Yibai Pharmaceutical Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

  • Current price-to-book ratio: 1.49x
  • The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
  • The price-to-book ratio has decreased from 26.76x to 1.49x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date Book Value per Share Market Price P/B Ratio
2001-12-31 CN¥0.18 CN¥4.70 x
2002-12-31 CN¥0.27 CN¥4.70 x
2003-12-31 CN¥0.38 CN¥4.70 x
2004-12-31 CN¥1.08 CN¥4.70 x
2005-12-31 CN¥1.18 CN¥4.70 x
2006-12-31 CN¥0.90 CN¥4.70 x
2007-12-31 CN¥0.94 CN¥4.70 x
2008-12-31 CN¥0.82 CN¥4.70 x
2009-12-31 CN¥0.99 CN¥4.70 x
2010-12-31 CN¥1.23 CN¥4.70 x
2011-12-31 CN¥1.60 CN¥4.70 x
2012-12-31 CN¥2.14 CN¥4.70 x
2013-12-31 CN¥2.67 CN¥4.70 x
2014-12-31 CN¥4.31 CN¥4.70 x
2015-12-31 CN¥4.47 CN¥4.70 x
2016-12-31 CN¥4.92 CN¥4.70 x
2017-12-31 CN¥5.34 CN¥4.70 x
2018-12-31 CN¥4.36 CN¥4.70 x
2019-12-31 CN¥4.55 CN¥4.70 x
2020-12-31 CN¥4.25 CN¥4.70 x
2021-12-31 CN¥4.42 CN¥4.70 x
2022-12-31 CN¥3.84 CN¥4.70 x
2023-12-31 CN¥3.64 CN¥4.70 x
2024-12-31 CN¥3.16 CN¥4.70 x

Capital Efficiency Dashboard

This dashboard shows how efficiently Guizhou Yibai Pharmaceutical Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

  • Current Return on Equity (ROE): -12.74%
  • The company may be facing challenges in efficiently utilizing shareholder equity.
  • DuPont Analysis Breakdown:
  • • Net Profit Margin: -14.59%
  • • Asset Turnover: 0.53x
  • • Equity Multiplier: 1.65x
  • Recent ROE (-12.74%) is below the historical average (10.41%), suggesting potential challenges in capital efficiency.

Historical Capital Efficiency Metrics

Year Return on Equity Net Profit Margin Asset Turnover Equity Multiplier Economic Value Added
2001 41.21% 12.31% 1.27x 2.64x CN¥25.79 Million
2002 35.55% 10.27% 1.46x 2.36x CN¥32.75 Million
2003 28.68% 10.26% 1.10x 2.53x CN¥33.58 Million
2004 11.10% 8.92% 0.73x 1.71x CN¥5.58 Million
2005 12.48% 9.39% 0.62x 2.16x CN¥13.79 Million
2006 -31.77% -18.76% 0.73x 2.33x CN¥-176.87 Million
2007 18.12% 9.22% 0.88x 2.23x CN¥41.57 Million
2008 16.94% 8.50% 0.95x 2.10x CN¥40.19 Million
2009 17.37% 9.32% 1.02x 1.83x CN¥51.69 Million
2010 22.58% 13.33% 0.94x 1.81x CN¥108.94 Million
2011 23.58% 13.95% 1.06x 1.60x CN¥152.89 Million
2012 21.66% 14.79% 0.99x 1.48x CN¥179.39 Million
2013 22.31% 15.41% 0.87x 1.66x CN¥236.77 Million
2014 13.51% 14.61% 0.57x 1.61x CN¥119.87 Million
2015 4.84% 5.18% 0.59x 1.58x CN¥-182.52 Million
2016 9.58% 10.12% 0.56x 1.69x CN¥-16.27 Million
2017 9.16% 10.18% 0.53x 1.70x CN¥-35.74 Million
2018 -20.99% -18.68% 0.60x 1.87x CN¥-1.07 Billion
2019 3.94% 4.22% 0.60x 1.56x CN¥-218.18 Million
2020 6.53% 6.44% 0.65x 1.55x CN¥-116.62 Million
2021 6.96% 7.28% 0.66x 1.45x CN¥-106.55 Million
2022 -14.40% -16.03% 0.56x 1.60x CN¥-742.75 Million
2023 3.58% 3.72% 0.60x 1.59x CN¥-185.05 Million
2024 -12.74% -14.59% 0.53x 1.65x CN¥-566.19 Million

Industry Comparison

This section compares Guizhou Yibai Pharmaceutical Co Ltd's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.

Industry Context

  • Industry: Drug Manufacturers - Specialty & Generic
  • Average net assets among peers: $1,469,607,050
  • Average return on equity (ROE) among peers: 6.32%

Peer Company Comparison

Company Net Assets Return on Equity Debt-to-Equity Market Cap
Guizhou Yibai Pharmaceutical Co Ltd (600594) CN¥2.52 Billion 41.21% 0.53x $373.03 Million
Shenzhen Neptunus Bioengineering Co Ltd (000078) $4.22 Billion -40.07% 6.66x $678.63 Million
Anhui Fengyuan Pharmaceutical Co Ltd (000153) $599.59 Million 1.51% 0.82x $321.53 Million
Shan Dong Dong-E E-Jiao Co Ltd (000423) $1.26 Billion 16.30% 0.27x $3.26 Billion
Wedge Industrial Co Ltd (000534) $0.00 0.00% 0.00x $1.65 Billion
Yunnan Baiyao Group Co Ltd (000538) $200.81 Million 8.75% 0.23x $5.55 Billion
Tus Pharmaceutical Group Co Ltd (000590) $702.49 Million 2.58% 0.66x $300.57 Million
Northeast Pharmaceutical Group Co Ltd (000597) $889.22 Million 5.34% 2.43x $424.80 Million
Jilin Aodong Pharmaceutical Group Co Ltd (000623) $4.89 Billion 40.71% 0.15x $1.92 Billion
Renhe Pharmacy Co Ltd (000650) $1.14 Billion 26.30% 0.40x $765.63 Million
Changchun High & New Technology Industries Group Inc (000661) $788.27 Million 1.76% 0.71x $3.27 Billion